- Home
- PEN
PEN
Penumbra Inc.
as 11-20-2024 4:00pm EST
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 7.0B | IPO Year: | 2015 |
| Target Price: | $232.23 | AVG Volume (30 days): | 416.9K |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.89 | EPS Growth: | -15.96 |
| 52 Week Low/High: | $148.00 - $277.34 | Next Earning Date: | 10-30-2024 |
| Revenue: | $1,163,776,000 | Revenue Growth: | 16.96% |
| Revenue Growth (this year): | 13.65% | Revenue Growth (next year): | 14.38% |
Stock Insider Trading Activity of Penumbra Inc. (PEN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Nov 15 '24 | Sell | $238.99 | 600 | $143,842.87 | 64,626 | |
| Elsesser Adam | PEN | CEO and President | Oct 21 '24 | Sell | $204.71 | 15,000 | $3,068,366.75 | 867,582 | |
| Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Oct 1 '24 | Sell | $191.07 | 600 | $114,455.67 | 64,626 | |
| Kassing Don W. | PEN | Director | Oct 1 '24 | Sell | $193.93 | 170 | $32,968.10 | 835 | |
| Elsesser Adam | PEN | CEO and President | Sep 20 '24 | Sell | $197.63 | 15,000 | $2,965,646.17 | 867,582 | |
| Grewal Harpreet | PEN | Director | Sep 4 '24 | Sell | $204.11 | 782 | $159,614.02 | 8,863 | |
| Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Sep 3 '24 | Sell | $206.04 | 600 | $123,732.57 | 64,626 |
Latest Penumbra Inc. News
PEN Breaking Stock News: Dive into PEN Ticker-Specific Updates for Smart Investing
PR Newswire
16 hours ago
Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference
Yahoo Finance
3 days ago
Inside a $400 billion bet on the brain-computer interface revolution
Insider Monkey
4 days ago
Penumbra, Inc. (PEN): A Bull Case Theory
Argus Research
9 days ago
PEN: Raising target price to $195.00
Simply Wall St.
14 days ago
There May Be Some Bright Spots In Penumbra's (NYSE:PEN) Earnings
Clinical Trials Arena
15 days ago
Penumbra reveals positive data for algorithm-assisted thrombectomy tech
Argus Research
16 days ago
PEN: Raising target price to $193.00
Zacks
16 days ago
Here is Why Growth Investors Should Buy Penumbra (PEN) Now
Compare PEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PEN Penumbra Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.